I graduated from the College of Pharmacy at the University of Baghdad in 2012, marking the beginning of a dedicated career in pharmaceutical sciences. With a strong foundation in pharmacy, I developed a keen interest in the complexities of drug action and safety. Driven by a desire to deepen my knowledge, I pursued a Master’s degree in Pharmacology and Toxicology at the same university, completing it in 2023. During this time, Iengaged in research that explored the effects of various substances on health, contributing valuable insights to the field.
Toxicological Effects of Natural Products: I aim to explore the safety profiles of natural compounds and their potential therapeutic benefits. This includes studying the toxicological effects of herbal medicines and dietary supplements, assessing their risks and benefits.
Development of Safer Therapeutics: My research seeks to contribute to the design and development of safer pharmacological agents. This involves investigating novel drug formulations and delivery systems that minimize adverse effects while maximizing therapeutic efficacy.
Environmental Toxicology: I am interested in the impact of environmental pollutants on human health, particularly how exposure to toxins can affect pharmacological responses and overall well-being.
Clinical Pharmacology: Understanding the implications of pharmacogenomics and individual variability in drug response is vital. I focus on how genetic factors influence drug metabolism and toxicity, aiming to personalize treatment regimens for better outcomes.
Through my research, I aspire to contribute to the advancement of pharmacological science and improve patient safety and health outcomes.
clinical toxicology pharmacology physiology
In this study, the possible protective effects of daidzein on ifosfamide-induced neurotoxicity in male rats were examined by the determination of changes in selected oxidant–antioxidant markers of male rats’ brain tissue.
Twenty-eight (28) apparently-healthy Wistar male rats weighing (120-150gm) allocated into 4 groups (n=7) were used in this study. Rats orally-administered 1% tween 20 dissolved in distilled water/Control (Group I); rats were orally-administered daidzein suspension (100mg/kg) for 7 days (Group II); rats intraperitoneally-injected with a single dose of ifosfamide (500 mg/kg) (Group III); rats orally-administered for 7 days with the daidzein (100mg/
... Show More
(1)
Ifosfamide (IFO), an alkylating chemotherapy agent, is known for its association with neurotoxicity and encephalopathy. This trial was designed to evaluate the protective action of daidzein (DZN) against IFO-induced neurotoxicity in male rats by determining the difference in certain inflammatory and apoptotic markers in the brain tissue of rats. Twenty-eight Wistar rats, weighing 120-150 g, were divided into four groups of seven rats: Group 1 (Control) received no treatment; Group 2 was orally administered DZN (100 mg/kg/day) for seven days; Group 3 received a single intraperitoneal (IP) dose of IFO (500 mg/kg); Group 4 received oral DZN (100 mg/kg/day) for one week prior to a single IP dose of IFO on the seventh day. Twenty-four hours post
... Show More
(1)
(1)